Avid Bioservices quality vice president Jeff Masten said the rollout of recent facility enhancements, as well as the plans for the next phases, requires timely, accurate and strategic execution across the organization.
”In completing this first phase ahead of schedule, teams from across the company worked together in unison to seamlessly implement these upgrades, while concurrently maintaining scheduled production, a reflection on the expertise and teamwork that we continually provide our clients," Masten added.
Avid Bioservices president Steven King said, "We are strategically reinvesting some of these financial resources back into the business to further increase manufacturing throughput, reduce manufacturing risks and ensure continued reliability with redundant systems."
The company is investing in the manufacturing infrastructure and systems to meet the anticipated needs of its clients and Peregrine’s advancing pipeline, including the commercialization of bavituximab and Cotara.
Avid, in the last quarter has increased its Reverse Osmosis Deionized (RODI) and Water for Injection (WFI) systems resulting in a 450% increase in water capacity, which allows for generation of sufficient water to support the anticipated increase in production.